Alicanto gains support from Nordgold at Arakaka

|

Published 19-JUN-2019 12:14 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Alicanto Minerals Ltd (ASX:AQI) has entered into an earn-in agreement with Nord Gold SE whereby Alicanto has granted Nordgold the exclusive right to acquire a 100% interest in the Arakaka Gold Project, Guyana.

Importantly, Nordgold has an outstanding track record in discovering and developing large-scale gold deposits in a number of regions, including South America.

The group has 10 producing mines in Burkina Faso, Guinea, Russia and Kazakhstan.

In terms of the agreement, Nordgold may earn up to a 100% interest in the Arakaka Project by fulfilling certain conditions.

The agreement would see Nordgold sole fund US$3 million in exploration expenditure within a one year earn-in period, and at completion of the earn-in period, pay an additional US$5 million to Alicanto as an “Earn-in Right”.

Alicanto would continue to operate the project during the first 12 months, and the drilling campaign would commence as soon as practicable with Nordgold required to spend a minimum of US$1.5 million.

If Nordgold terminates the agreement and ceases to make contributions at any time during the earn-in period the company will forfeit all rights and interests to the Arakaka Gold Project.

Complementary to proposed VMS acquisition

While this is a significant development in terms of progressing the Arakaka Gold Project, Alicanto has taken on another dimension since entering into an option and share sale agreement to acquire the Oxberg and Naverberg VMS (Volcanogenic Massive Sulphide) projects in Sweden.

Alicanto has entered into an option and share sale agreement to acquire the Oxberg and Naverberg projects.

The area is highly prospective for zinc, lead, silver, copper and gold with the broader district home to world-class producing mines that feature impressive grades.

The company has immediate multiple walk up high grade VMS drill targets at Naverberg with rock chip samples including 26.1% zinc, 8.8% zinc and 2.4% copper.

Alicanto intends to explore the Oxberg and Naverberg Project area in the next 12 months following shareholder approval of the transaction.

Management plans to undertake data compilation, field mapping, and surface geochemical sampling ahead of proposed drilling in the second half of the year.

Following shareholder approval, Alicanto will now be delivering market sensitive news flow on multiple fronts, making it a stock to watch in 2019/2020.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X